For: | Lodhia N, Rao S. Updates in therapeutic drug monitoring in inflammatory bowel disease. World J Gastroenterol 2022; 28(21): 2282-2290 [PMID: 35800180 DOI: 10.3748/wjg.v28.i21.2282] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v28/i21/2282.htm |
Number | Citing Articles |
1 |
Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Eirini Theodoraki, Ioannis E. Koutroubakis. Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease. Journal of Clinical Medicine 2023; 12(7): 2452 doi: 10.3390/jcm12072452
|
2 |
Yoav Hershkovitz, Israel Khanimov, Limor Rubin, Zvika Dranitzki, Aviv Talmon, Yaarit Ribak, Oded Shamriz, Asi Levi, Yuval Tal. Successful ligelizumab treatment of severe refractory solar urticaria. The Journal of Allergy and Clinical Immunology: In Practice 2023; 11(8): 2576 doi: 10.1016/j.jaip.2023.01.052
|
3 |
Agata Michalak, Beata Kasztelan-Szczerbińska, Halina Cichoż-Lach. Impact of Obesity on the Course of Management of Inflammatory Bowel Disease—A Review. Nutrients 2022; 14(19): 3983 doi: 10.3390/nu14193983
|
4 |
Likang Xu, Jinzhao Zou, Chao Sun, Gong Chen, Sujun Gao. Worldwide research trends in Crohn’s disease treatment over the past 2 decades: a bibliometric analysis. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1441785
|
5 |
Jeffrey A. Lowell, Garvita Sharma, Vincent Chua, Shomron Ben-Horin, Arun Swaminath, Keith Sultan. Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis. Digestive Diseases and Sciences 2024; 69(10): 3920 doi: 10.1007/s10620-024-08515-5
|